Shares of Novo Nordisk and Eli Lilly have surged on strong demand for their diabetes and obesity medications like Ozempic, Wegovy, and Mounjaro. Investors are betting on years of blockbuster sales and profits from the obesity epidemic. The drugs are forecast to reach $53 billion in combined revenue by 2028. Enthusiasm for weight-loss drugs has outweighed challenges facing the broader pharmaceutical industry like fading COVID-19 sales, drug pricing reforms, and patent expirations. Some investors see beaten-down pharma stocks like Pfizer as undervalued given their technology and potential, while weight-loss stocks are priced for perfection, leaving little room for disappointment.
Category
🗞
NewsTranscript
00:00 Benzinga and here's what's on the block. Shares of Eli Lilly have surged on strong demand for
00:05 the diabetes and obesity medications like Ozempic. Investors are betting on years of blockbuster
00:10 sales and profits from the obesity epidemic. The drugs are forecast to reach $53 billion
00:15 in combined revenue by 2028. Enthusiasm for the weight loss drugs has outweighed challenges facing
00:22 the broader pharmaceutical industry like fading COVID-19 sales, drug pricing reforms, and patent
00:27 expirations. Some investors see beaten down pharma stocks like Pfizer as undervalued given their
00:32 technology and potential while weight loss stocks are priced for perfection leaving little to no
00:37 room for disappointment. For all things money visit Benzinga.com